丁型肝炎抗病毒治疗药物的研究进展

Research advances in antiviral drugs for the treatment of hepatitis

丁型肝炎病毒(HDV)是一种乙型肝炎病毒(HBV)的卫星病毒,需借助HBV包膜蛋白完成自身的组装和复制,进而建立新的感染。慢性HDV感染是病毒性肝炎最严重的形式,可加速疾病进展,提高肝癌的发生风险,HDV感染者迫切需要有效的抗病毒治疗以缓解疾病进展,但能够用于抗HDV感染的治疗药物仅包括2020年7月欧洲药品管理局有条件批准的Bulevirtide以及之前推荐使用的干扰素。目前,针对病毒复制周期的几种靶向抗病毒药物正在研究中,且前期临床试验结果表现良好。这意味着HDV的抗病毒药物研发取得了重要突破,为丁型肝炎的治疗带来了希望。本文就目前丁型肝炎抗病毒药物进行简要综述,并对相关的治疗方案进行了讨论,为丁型肝炎的治疗提供参考。

Hepatitis D virus(HDV)is a satellite virus of hepatitis B virus(HBV)and needs the help of HBV envelope protein to complete its own assembly and replication and then establish a new infection cycle.Chronic HDV infection is considered the most severe form of viral hepatitis,which can accelerate disease progression and increase the risk of liver cancer.Effective antiviral therapy is urgently needed to delay disease progression in patients with HDV infection,but Bulevirtide conditionally approved by European Medicines Agency in July 2020 and interferon previously recommended are the only drugs used for the treatment of HDV infection.At present,studies are being conducted for several antiviral drugs targeting viral replication cycle,and early clinical trials have obtained good results.This means that important breakthroughs have been made in the development of antiviral drugs,bringing hope for the treatment of hepatitis D.This article summarizes the current antiviral drugs for hepatitis D and discusses related treatment regimens,so as to provide a reference for the treatment of hepatitis D.